Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367408 | 0.84 | PTGDR2 (0.69) | PTGDR2PPARGPPARAPPARDFFAR1 | |
| SCHEMBL1369142 | 0.82 | KDR (0.47) | LTA4HKDR | |
| SCHEMBL1369635 | 0.81 | PTGDR2 (0.71) | PTGDR2PPARGPPARAPPARDFFAR1 | |
| SCHEMBL1369034 | 0.81 | PTGDR2 (0.52) | PTGDR2PPARGPPARAPPARDTP53 | |
| SCHEMBL2486677 | 0.80 | PTGDR2 (0.49) | PTGDR2PPARGPPARAPPARDFFAR1 | |
| SCHEMBL1366570 | 0.79 | PARP1 (0.38) | ADRA1AHRH1HRH3 | |
| SCHEMBL1367124 | 0.78 | L3MBTL1 (0.38) | — | |
| SCHEMBL1369734 | 0.78 | SLC1A5 (0.49) | TP53 | |
| SCHEMBL14859707 | 0.76 | MAPT (0.48) | PTGDR2TP53 | |
| SCHEMBL14859479 | 0.76 | MAPT (0.46) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2377851-A1 | ISOQUINOLINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | HRH1, HRH2, HRH4 | PTGDR2 189/4885PPARG 1874/4885PPARA 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.